OriC902 / Oricell - LARVOL DELTA

Oricell Therapeutics Announces US$70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies (PRNewswire) - "Proceeds will accelerate Oricell's global expansion and clinical development, while strengthening its technological capabilities and paving ways to commercialization....Oricell has generated proof-of-concept (POC) clinical data across multiple pipeline CAR-T products. Its lead program, Ori-C101, is an autologous GPC3-targeted CAR-T therapy for advanced hepatocellular carcinoma (HCC)....The innovative secreting CAR-T, OriC902, has shown groundbreaking efficacy and durability in ultra-late-line and difficult-to-treat solid tumor patients."

Financing • Hepatocellular Cancer